睿知中国医院研究地图
候选清单

正在招募胃癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

ClinicalTrials.gov 上登记的一项胃癌开放试验,由深圳大学总医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方深圳大学总医院Shenzhen University General Hospital深圳医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05620732,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);

    入选标准第 3 条

  3. According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)<50% by echocardiography;

    排除标准第 4 条

  4. Grade 3 hypertension and poor blood pressure control after drug treatment;

    排除标准第 7 条

  5. ECOG score is 0-2;

    入选标准第 9 条

  6. The following conditions occur in blood routine examination: WBC ≤ 1 × 109/L, absolute value of central granulocyte ANC ≤ 0.5 × 109/L, absolute value of lymphocyte ALC ≤ 0.5 × 109/L , PLT≦25 × 109/L ;

    排除标准第 2 条

    The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg/dl;

    排除标准第 3 条

  7. According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;

    入选标准第 4 条

  8. HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;

    排除标准第 13 条

  9. Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05620732,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-75 (≥ 18, ≤ 75), regardless of gender;
  2. Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
  3. Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);
  4. According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;
  5. Immunohistochemical staining confirmed that Claudin 18.2 was moderately and highly expressed in tumor tissues;
  6. Subjects must have received the first and second line standard treatment scheme;
  7. The subject must not be suitable for receiving radical treatment methods, such as radical chemotherapy and radiotherapy and/or surgery/immunosuppressant at the checkpoint, or refuse surgical resection
  8. Within 2 weeks before cell therapy, no antibody drugs were used;
  9. ECOG score is 0-2;
  10. The subjects had no contraindication for peripheral blood collection;
  11. The expected survival period is more than 3 months.

排除标准:Exclusion Criteria:

  1. People who have a history of allergy to any component in cell products;
  2. The following conditions occur in blood routine examination: WBC ≤ 1 × 109/L, absolute value of central granulocyte ANC ≤ 0.5 × 109/L, absolute value of lymphocyte ALC ≤ 0.5 × 109/L , PLT≦25 × 109/L ;
  3. The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg/dl;
  4. According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)<50% by echocardiography;
  5. Pulmonary function is abnormal, and the saturation of blood oxygen under indoor air is less than 92%;
  6. Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart diseases clinically within 12 months before enrollment;
  7. Grade 3 hypertension and poor blood pressure control after drug treatment;
  8. Have suffered from brain trauma, consciousness disorder, epilepsy, relatively serious cerebral ischemia or cerebral hemorrhage disease in the past;
  9. Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressive treatment;
  10. There is uncontrolled active infection;
  11. Have used any CAR-T cell product or other genetically modified T cell therapy before;
  12. Live vaccine inoculation within 4 weeks before enrollment;
  13. HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;
  14. Subjects have a history of alcohol abuse, drug abuse or mental illness;
  15. Subjects have participated in any other clinical research within 3 months before joining this clinical research;
  16. Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;
  17. The investigator believes that there are other circumstances that are not suitable for the subject to participate in this study

引自 ClinicalTrials.gov, NCT05620732, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05620732,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05620732